JP7173733B2 - Ｐｄ－１遮断による免疫療法の癌奏効の決定因子 - Google Patents

Ｐｄ－１遮断による免疫療法の癌奏効の決定因子 Download PDF

Info

Publication number
JP7173733B2
JP7173733B2 JP2017527368A JP2017527368A JP7173733B2 JP 7173733 B2 JP7173733 B2 JP 7173733B2 JP 2017527368 A JP2017527368 A JP 2017527368A JP 2017527368 A JP2017527368 A JP 2017527368A JP 7173733 B2 JP7173733 B2 JP 7173733B2
Authority
JP
Japan
Prior art keywords
cancer
immune checkpoint
response
patients
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017527368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502828A5 (enExample
JPWO2016081947A5 (enExample
JP2018502828A (ja
Inventor
ティモシー エイ． チャン
ナイヤー エイ． リズビ
マシュー ディー． ヘルマン
Original Assignee
メモリアル スローン ケタリング キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2018502828A publication Critical patent/JP2018502828A/ja
Publication of JP2018502828A5 publication Critical patent/JP2018502828A5/ja
Priority to JP2022129458A priority Critical patent/JP7550193B2/ja
Publication of JPWO2016081947A5 publication Critical patent/JPWO2016081947A5/ja
Application granted granted Critical
Publication of JP7173733B2 publication Critical patent/JP7173733B2/ja
Priority to JP2024107117A priority patent/JP2024125234A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017527368A 2014-11-21 2015-11-23 Ｐｄ－１遮断による免疫療法の癌奏効の決定因子 Active JP7173733B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022129458A JP7550193B2 (ja) 2014-11-21 2022-08-16 Ｐｄ－１遮断による免疫療法の癌奏効の決定因子
JP2024107117A JP2024125234A (ja) 2014-11-21 2024-07-03 Ｐｄ－１遮断による免疫療法の癌奏効の決定因子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462083088P 2014-11-21 2014-11-21
US62/083,088 2014-11-21
US201562132381P 2015-03-12 2015-03-12
US62/132,381 2015-03-12
PCT/US2015/062208 WO2016081947A2 (en) 2014-11-21 2015-11-23 Determinants of cancer response to immunotherapy by pd-1 blockade

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020135853A Division JP2020196732A (ja) 2014-11-21 2020-08-11 Ｐｄ−１遮断による免疫療法の癌奏効の決定因子
JP2022129458A Division JP7550193B2 (ja) 2014-11-21 2022-08-16 Ｐｄ－１遮断による免疫療法の癌奏効の決定因子

Publications (4)

Publication Number Publication Date
JP2018502828A JP2018502828A (ja) 2018-02-01
JP2018502828A5 JP2018502828A5 (enExample) 2019-01-10
JPWO2016081947A5 JPWO2016081947A5 (enExample) 2022-09-01
JP7173733B2 true JP7173733B2 (ja) 2022-11-16

Family

ID=56014697

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017527368A Active JP7173733B2 (ja) 2014-11-21 2015-11-23 Ｐｄ－１遮断による免疫療法の癌奏効の決定因子
JP2020135853A Withdrawn JP2020196732A (ja) 2014-11-21 2020-08-11 Ｐｄ−１遮断による免疫療法の癌奏効の決定因子
JP2022129458A Active JP7550193B2 (ja) 2014-11-21 2022-08-16 Ｐｄ－１遮断による免疫療法の癌奏効の決定因子
JP2024107117A Pending JP2024125234A (ja) 2014-11-21 2024-07-03 Ｐｄ－１遮断による免疫療法の癌奏効の決定因子

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020135853A Withdrawn JP2020196732A (ja) 2014-11-21 2020-08-11 Ｐｄ−１遮断による免疫療法の癌奏効の決定因子
JP2022129458A Active JP7550193B2 (ja) 2014-11-21 2022-08-16 Ｐｄ－１遮断による免疫療法の癌奏効の決定因子
JP2024107117A Pending JP2024125234A (ja) 2014-11-21 2024-07-03 Ｐｄ－１遮断による免疫療法の癌奏効の決定因子

Country Status (9)

Country Link
US (3) US20180291074A1 (enExample)
EP (2) EP3220950A4 (enExample)
JP (4) JP7173733B2 (enExample)
CN (2) CN107206064B (enExample)
AU (3) AU2015349644B2 (enExample)
CA (1) CA2968059A1 (enExample)
HK (1) HK1244440A1 (enExample)
MA (1) MA40737A (enExample)
WO (1) WO2016081947A2 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
PE20160953A1 (es) 2013-12-12 2016-09-26 Shanghai hengrui pharmaceutical co ltd Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
US9765147B2 (en) 2014-10-29 2017-09-19 Five Prime Therapeutics, Inc. Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
CA3008437A1 (en) 2016-01-08 2017-07-13 Vaccibody As Therapeutic anticancer neoepitope vaccine
CN109196121B (zh) 2016-02-29 2022-01-04 基因泰克公司 用于癌症的治疗和诊断方法
JP2019509282A (ja) 2016-02-29 2019-04-04 ファウンデーション・メディシン・インコーポレイテッド 癌の治療方法
EP3804620B1 (en) * 2016-03-01 2022-02-16 North Carolina State University Enhanced cancer immunotherapy by microneedle patch-assisted delivery
BR112018016920A2 (pt) * 2016-03-02 2019-01-02 Toray Industries, Inc. indutor da imunidade, célula apresentadora de antígeno isolada, célula t isolada, polipeptídeo, agente para tratar ou prevenir o câncer e método de tratamento ou prevenção do câncer
MA45123A (fr) 2016-05-27 2019-04-10 Agenus Inc Anticorps anti-tim-3 et leurs méthodes d'utilisation
WO2018003995A1 (ja) * 2016-07-01 2018-01-04 国立大学法人東北大学 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法
US11875877B2 (en) 2016-08-25 2024-01-16 Nantomics, Llc Immunotherapy markers and uses therefor
CA3038712A1 (en) * 2016-10-06 2018-04-12 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2018067937A1 (en) 2016-10-07 2018-04-12 Omniseq, Inc. Methods and systems for determining personalized therapies
WO2018132753A1 (en) * 2017-01-13 2018-07-19 Nantbio, Inc. Validation of neoepitope-based treatment
US12331359B2 (en) 2017-01-18 2025-06-17 Michael Laessig Neoantigens and uses thereof for treating cancer
EP3576780A1 (en) 2017-02-01 2019-12-11 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
WO2018145023A1 (en) * 2017-02-06 2018-08-09 Novartis Ag Method of predicting response to immunotherapy
WO2018151601A1 (en) * 2017-02-17 2018-08-23 Stichting Vumc Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets
SG11201908530QA (en) 2017-03-20 2019-10-30 Genocea Biosciences Inc Treatment methods
KR20250036268A (ko) * 2017-03-31 2025-03-13 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
GB201710815D0 (en) * 2017-07-05 2017-08-16 Francis Crick Inst Ltd Method
IL271888B2 (en) 2017-07-21 2024-09-01 Genentech Inc Therapeutic and diagnostic methods for cancer
EP3658914A1 (en) * 2017-07-28 2020-06-03 Bristol-Myers Squibb Company Predictive peripheral blood biomarker for checkpoint inhibitors
MX2020002301A (es) * 2017-09-13 2020-07-13 Five Prime Therapeutics Inc Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico.
US20200268831A1 (en) * 2017-09-15 2020-08-27 The Texas A&M University System Methods for enhancing immunotherapy in the treatment of cancer
CN111432837A (zh) 2017-09-25 2020-07-17 纪念斯隆凯特琳癌症中心 肿瘤突变负荷和检查点免疫疗法
US20200362418A1 (en) * 2017-10-02 2020-11-19 Curematch, Inc. Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
US11810672B2 (en) 2017-10-12 2023-11-07 Nantomics, Llc Cancer score for assessment and response prediction from biological fluids
JP2020536894A (ja) 2017-10-15 2020-12-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍処置法
EP3704268B1 (en) 2017-11-03 2025-01-22 Guardant Health, Inc. Normalizing tumor mutation burden
WO2019095017A1 (en) * 2017-11-17 2019-05-23 Gmdx Co Pty Ltd Systems and methods for predicting the efficacy of cancer therapy
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
WO2019109086A1 (en) * 2017-12-01 2019-06-06 Illumina, Inc. Methods and systems for determining somatic mutation clonality
JP6975350B2 (ja) * 2018-05-03 2021-12-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 腫瘍突然変異量の測定のための代理マーカーおよび方法
WO2019211489A1 (en) * 2018-05-04 2019-11-07 Merck Patent Gmbh COMBINED INHIBITION OF PD-1/PD-L1, TGFβ AND DNA-PK FOR THE TREATMENT OF CANCER
CN120193081A (zh) 2018-07-23 2025-06-24 夸登特健康公司 用于通过肿瘤分数和覆盖率调整肿瘤突变负荷的方法和系统
US20210292851A1 (en) 2018-07-27 2021-09-23 Roche Sequencing Solutions, Inc. Method of monitoring effectiveness of immunotherapy of cancer patients
EP3845236A4 (en) * 2018-08-29 2022-07-27 Tokyo Metropolitan Institute of Medical Science ANTI-TUMOR AGENT TARGETING AN HGF-REGULATED TYROSINE KINASE (HGS) SUBSTRATE
AU2019328344B2 (en) 2018-08-31 2025-06-12 Guardant Health, Inc. Microsatellite instability detection in cell-free DNA
WO2020102674A1 (en) * 2018-11-15 2020-05-22 Personal Genome Diagnostics Inc. Method of improving prediction of response for cancer patients treated with immunotherapy
WO2020121226A1 (en) * 2018-12-12 2020-06-18 Medimmune, Llc Blood-based tumor mutation burden predicts overall survival in non-small cell lung cancer
EP3982954A4 (en) * 2019-06-14 2024-01-03 The Trustees of Columbia University in the City of New York NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA
WO2021087381A1 (en) * 2019-11-01 2021-05-06 Memorial Sloan Kettering Cancer Center Hla class i sequence divergence and cancer therapy
GB202003669D0 (en) * 2020-03-13 2020-04-29 Univ Oxford Innovation Ltd Method for identifying neo-antigens
CN115885050A (zh) 2020-04-28 2023-03-31 基因泰克公司 用于非小细胞肺癌免疫疗法的方法和组合物
EP4158070A4 (en) * 2020-06-01 2025-05-07 GMDx Co Pty Ltd METHODS FOR PREDICTING CANCER PROGRESSION
CN112309502B (zh) * 2020-10-14 2024-09-20 深圳市新合生物医疗科技有限公司 一种计算肿瘤新抗原负荷的方法及系统
WO2022099004A1 (en) * 2020-11-06 2022-05-12 The General Hospital Corporation Methods for characterizing biological samples
WO2022235482A1 (en) * 2021-05-03 2022-11-10 Rutgers, The State University Of New Jersey Immunotherapy for inflammatory bowel disease and/or cancer
CN113030475B (zh) * 2021-05-25 2021-08-10 泛肽生物科技(浙江)有限公司 一种基于细胞线粒体质量评估的t细胞pd-1检测方法
CN113355424B (zh) * 2021-07-14 2022-03-25 江苏先声医学诊断有限公司 Pcdh11x突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用
WO2024216165A1 (en) 2023-04-12 2024-10-17 Icahn School Of Medicine At Mount Sinai Computational methods for selecting personalized neoantigen vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533082A (ja) 2012-09-28 2015-11-19 ユニバーシティ オブ コネチカット 癌の治療のための腫瘍防御エピトープの同定

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033497A1 (en) 2002-08-13 2004-02-19 Alarcon-Riquelme Marta E. Polymorphisms of PD-1
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
EP2499486A4 (en) * 2009-11-13 2013-11-27 Infinity Pharmaceuticals Inc COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, EVALUATION, PREVENTION, AND THERAPY OF CANCER
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
KR101958753B1 (ko) * 2010-04-13 2019-03-15 셀덱스 쎄라퓨틱스, 인크. 인간 ｃｄ27에 결합하는 항체 및 이의 용도
KR102315754B1 (ko) * 2010-05-14 2021-10-22 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
US20130225433A1 (en) * 2012-02-29 2013-08-29 The Regents Of The Universitys Of Michagan Prostate cancer markers and uses thereof
NZ701324A (en) 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
KR20160102314A (ko) * 2014-01-02 2016-08-29 메모리얼 슬로안-케터링 캔서 센터 면역 치료요법에 대한 암 반응의 결정인자
CA2966660A1 (en) * 2014-11-13 2016-05-19 The Johns Hopkins University Checkpoint blockade and microsatellite instability
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
CN111432837A (zh) * 2017-09-25 2020-07-17 纪念斯隆凯特琳癌症中心 肿瘤突变负荷和检查点免疫疗法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533082A (ja) 2012-09-28 2015-11-19 ユニバーシティ オブ コネチカット 癌の治療のための腫瘍防御エピトープの同定

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ＪＯＵＲＮＡＬ ＯＦ ＢＩＯＭＥＤＩＣＩＮＥ ＡＮＤ ＢＩＯＴＥＣＨＮＯＬＯＧＹ，２０１０．０７．１７．，ＶＯＬ．２０１０，ＮＯ．１０２７５８，Ｐ．１－１２
ＯＮＣＯＩＭＭＵＮＯＬＯＧＹ，２０１４．０１．，ＶＯＬ．３，ｅ２７８１７，Ｐ．１－６
ＯＮＣＯＩＭＭＵＮＯＬＯＧＹ，２０１４．１１．０１．，ＶＯＬ．３，ＮＯ．１１，ｅ９６７１４７，Ｐ．１－５
ＴＨＥ ＮＥＷ ＥＮＧＬＡＮＤ ＪＯＵＲＮＡＬ ＯＦ ＭＥＤＩＣＩＮＥ，２０１４．１１．０９．，ＶＯＬ．３７１，Ｐ．２１８９－２１９９

Also Published As

Publication number Publication date
WO2016081947A3 (en) 2016-07-07
AU2024278364A1 (en) 2025-02-13
AU2015349644B2 (en) 2021-08-19
CN107206064A (zh) 2017-09-26
US20200040049A1 (en) 2020-02-06
US10993998B2 (en) 2021-05-04
JP7550193B2 (ja) 2024-09-19
HK1244440A1 (zh) 2018-08-10
WO2016081947A2 (en) 2016-05-26
JP2023055625A (ja) 2023-04-18
CA2968059A1 (en) 2016-05-26
JP2020196732A (ja) 2020-12-10
AU2021215099A1 (en) 2021-08-26
CN107206064B (zh) 2021-12-21
JP2018502828A (ja) 2018-02-01
JP2024125234A (ja) 2024-09-13
MA40737A (fr) 2017-07-04
US20210308241A1 (en) 2021-10-07
AU2015349644A1 (en) 2017-06-15
EP4393546A2 (en) 2024-07-03
US12485162B2 (en) 2025-12-02
WO2016081947A4 (en) 2016-09-09
US20180291074A1 (en) 2018-10-11
CN114672559A (zh) 2022-06-28
EP3220950A2 (en) 2017-09-27
EP4393546A3 (en) 2024-12-11
EP3220950A4 (en) 2018-08-29

Similar Documents

Publication Publication Date Title
JP7550193B2 (ja) Ｐｄ－１遮断による免疫療法の癌奏効の決定因子
US20220340663A1 (en) Tumor mutational load
RU2707530C2 (ru) Детерминанты ответа раковой опухоли на иммунотерапию
JP2024119815A (ja) 腫瘍を処置する方法
WO2018183928A1 (en) Methods of treating tumor
US20220389102A1 (en) Hla class i sequence divergence and cancer therapy
US20230002490A1 (en) Determinants of cancer response to immunotherapy
HK40098129A (en) Tumor mutational load and checkpoint immunotherapy
You et al. Comprehensive Immune Landscape and Molecular Characteristics of Clinical Responses to Chemotherapy, Antiangiogenic Agents and PD-1 Inhibitors in Advanced Nasopharyngeal Cancer
HK40115175A (en) Determinants of cancer response to immunotherapy by pd-1 blockade
HK40032690A (en) Tumor mutational load and checkpoint immunotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200306

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200811

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200819

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200910

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200914

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20201023

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20201028

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210525

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210707

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220316

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20220316

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220413

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220615

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220816

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220907

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20221006

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20221006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221104

R150 Certificate of patent or registration of utility model

Ref document number: 7173733

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250